Diagnostics company opens new facility to scale up production of IsoPSA test for prostate cancer
June 29th 2023The new space includes a clinical laboratory for IsoPSA testing, labs for research and development, offices, and manufacturing spaces for production and distribution of in vitro diagnostic kits.
PSMA-PET imaging product Illuccix officially launches in Canada for prostate cancer
May 5th 2023Illuccix is approved by Health Canada for imaging in patients with suspected metastasis who are candidates for initial definitive therapy, or in patients with suspected recurrence based on an elevated PSA level.
FDA panel recommends limiting potential approval of olaparib/abiraterone to frontline BRCA+ mCRPC
May 2nd 2023The indication is restricted from the indication in the FDA supplemental New Drug Application for olaparib/abiraterone, which is for the population at-large in the BRCA–mutation positive setting.